AstraZeneca reaches settlement agreement resolving patent litigation related to Ultomiris.
Alexion, AstraZeneca’s Rare Disease group, has entered into a settlement agreement with Chugai Pharmaceutical Co., Ltd. (Chugai), resolving all patent disputes between the two companies related to Ultomiris (ravulizumab). In accordance with the settlement agreement, Alexion and Chugai have taken steps to withdraw patent infringement proceedings filed with US District Court for the District of Delaware and Tokyo District Court.
Under the terms of the agreement, Alexion will make a single payment of $775 million in the second quarter of 2022, for which a charge will be recognised through the non-core P&L in the first quarter of 2022. No further amounts are payable by either party. The settlement does not impact AstraZeneca’s financial guidance for 2022.
Related news and insights
BioCryst Pharmaceuticals announced that the FDA has lifted its partial clinical hold on the BCX 9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX 9930.
Samsung Bioepis Co., Ltd. announced that SB 12, a proposed biosimilar to Soliris (eculizumab), showed clinical equivalence in efficacy, safety, PK, PD and immunogenicity between SB 12 and reference eculizumab in patients with PNH.
Swedish Orphan Biovitrum AB (publ) (Sobi) and Apellis Pharmaceuticals, Inc. reported new analyses of phase III studies that reinforce the robust efficacy and safety profile of Aspaveli/Empaveli (pegcetacoplan) for paroxysmal nocturnal haemoglobinuria (PNH) . The data will be presented at the hybrid European Hematology Association (EHA) Congress in Vienna, Austria.